SC seeks Centre’s reply on plea alleging no approval for Remdesivir, Favipiravir

The Supreme Court Thursday sought response from the Centre on a plea alleging that two medicines Remdesivir and Favipiravir, are being used for treatment of COVID-19 without approval.

A bench headed by Chief Justice S A Bobde issued notice to the Centre on the plea and sought its response in four weeks.

Advocate M L Sharma petitioner in-person referred to the bench, also comprising Justices A S Bopanna and V Ramasubramanian, the World Health Organization (WHO) report of October 15 and said that nowhere these medicines are designated officially as medicines for coronavirus.

The bench said that it is only going to make central government aware of it and therefore issuing notice.